Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...
People in New Zealand living with a rare type of blood cancer, systemic anaplastic large cell lymphoma (sALCL), could benefit from wider access to brentuximab vedotin under a proposal from Pharmac.
Breyanzi is approved for relapsed or refractory marginal zone lymphoma after two prior systemic therapies, showing high response rates in clinical trials. The TRANSCEND FL-MZL Cohort trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results